You should not be invested in either company if you can't answer 1 or 2. It means you don't have any grasp of the history or science.
Why is TCRT hated by the street? Why should it deserve anything else. Boyle is incentivized to sell the company ASAP and nobody is biting apparently.
2nd Gen Sleeping Beauty failed compared to Kymriah, Yescarta and Breyanzi. It makes sense POC also failed. Instead, old management pumped a failed IL-12 platform. Even if TCRT does show success, it's unlikely due to SB. It's going to be about the right cells with the right phenotypes, not the mechanism about how we created it and how much it cost. That comes in future modifications like T-Charge will be for Car-T.
Neogene being acquired isn't cause for joy. Their potential IPO and its potential for wild overvaluation (see ALLO) removes one of the biggest reasons for large valuation in TCRT. They still had a bunch of cash from their $110m Series A, which is likely being used towards the non-contingent consideration of $120m in the form of retention of Schumacher et al. Arie now has 4 SM companies acquired by big pharma. And CDL too. Kite leaving TCR and Arie selling Neogene means something.
We collectively suck at this right now. Everybody wants to portray they have the secret antidote (inhibigen is my favorite bullshit word), when in reality whoever can get TIL to work decently in lung cancer wins.
In the meantime, TCRT struggling to enroll is a death signal for the company. There seems to be limited stickiness to TCR efficacy. It will take years to prove otherwise. MDA will likely pick the carcass for internal uses.